- Home
- ACAD vs ADX Comparison
ACAD vs ADX Comparison
Compare ACAD & ADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ADX
- Stock Information
- Founded
- ACAD 1993
- ADX 1840
- Country
- ACAD United States
- ADX United States
- Employees
- ACAD N/A
- ADX N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ADX Investment Managers
- Sector
- ACAD Health Care
- ADX Finance
- Exchange
- ACAD Nasdaq
- ADX Nasdaq
- Market Cap
- ACAD 2.8B
- ADX 2.3B
- IPO Year
- ACAD 2004
- ADX N/A
- Fundamental
- Price
- ACAD $16.61
- ADX $19.02
- Analyst Decision
- ACAD Buy
- ADX
- Analyst Count
- ACAD 17
- ADX 0
- Target Price
- ACAD $24.00
- ADX N/A
- AVG Volume (30 Days)
- ACAD 1.5M
- ADX 182.4K
- Earning Date
- ACAD 05-07-2025
- ADX 01-01-0001
- Dividend Yield
- ACAD N/A
- ADX 6.68%
- EPS Growth
- ACAD N/A
- ADX N/A
- EPS
- ACAD 1.36
- ADX N/A
- Revenue
- ACAD $957,797,000.00
- ADX N/A
- Revenue This Year
- ACAD $13.07
- ADX N/A
- Revenue Next Year
- ACAD $9.97
- ADX N/A
- P/E Ratio
- ACAD $12.28
- ADX N/A
- Revenue Growth
- ACAD 31.85
- ADX N/A
- 52 Week Low
- ACAD $14.15
- ADX $14.94
- 52 Week High
- ACAD $20.68
- ADX $19.57
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- ADX 40.57
- Support Level
- ACAD $16.86
- ADX $18.86
- Resistance Level
- ACAD $17.31
- ADX $19.48
- Average True Range (ATR)
- ACAD 0.51
- ADX 0.30
- MACD
- ACAD -0.00
- ADX 0.05
- Stochastic Oscillator
- ACAD 23.24
- ADX 48.45
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ADX Adams Diversified Equity Fund Inc.
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally-managed closed-end fund. The investment objectives of the company are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It has a diversified equity portfolio which consists of securities of companies from Energy, Consumer Staples, Information Technology, Financials and other sectors.